$109 Million

Versartis

Sell-side

Exclusive Financial Advisor, June 2018

Merger with Aravive Biologics, Inc.

Versartis is an endocrine-focused biopharmaceutical company initially developing its novel long-acting recombinant human growth hormone, Somavaratan (VRS-317), for growth hormone deficiency, or GHD, an orphan disease. A key limitation to current recombinant human growth hormone, or rhGH, products is that they impose the burden of daily injections over multiple years, often resulting in poor compliance, which in turn can lead to suboptimal treatment outcomes in GHD patients. Despite this limitation, global annual sales from marketed rhGH products were over $3 billion in 2015. Somavaratan is intended to reduce the burden of daily treatment by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. The Company’s first targeted indication for Somavaratan is pediatric GHD, which represents an approximately $1.5 billion existing market opportunity

More Like This

Jul 2023

Sold Majority Stake in hg medical to Astorg Mid-Cap

Exclusive Financial Advisor

View Details >
May 2023
Jounce Therapeutics Logo

Acquired by Concentra Biosciences

Exclusive Financial Advisor

View Details >
Mar 2023

Smile Source, a Portfolio Company of Brazos Private Equity Partners, has Partnered with Incline Equity Partners

Exclusive Financial Advisor

View Details >